One author replies

American Journal of Epidemiology

Volumn 180, Issue 12, 2014, Pages 1217-1218

  Zhang, Zhi Jiang ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

CANCER RISK; DEPENDENT VARIABLE; DRUG EXPOSURE; HUMAN; LETTER; LUNG CANCER; MEDICAL RESEARCH; TIME; DIABETES MELLITUS, TYPE 2; LUNG NEOPLASMS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; METFORMIN;

EID: 84922349119     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu314     Document Type: Letter

References (16)

1. Schmedt N, Azoulay L, Hense S. Re: "Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis" [letter]. Am J Epidemiol. 2014; 180(12):1216-1217.
2. Zhang ZJ, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol. 2014;180(1): 11-14.
3. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665-2673.
4. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34(10): 2323-2328.
5. Zhang ZJ, Zheng ZJ, Shi R, et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(7): 2347-2353.
6. Smiechowski BB, Azoulay L, Yin H, et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care. 2013;36(1):124-129.
7. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large populationbased follow-up study. Diabetes Care. 2012;35(1): 119-124.
8. Ferrara A, Lewis JD, Quesenberry CP Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34(4):923-929.
9. Mazzone PJ, Rai H, Beukemann M, et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 2012;12:410.
10. Hsieh MC, Lee TC, Cheng SM, et al. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:413782.
11. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9): 1620-1625.
12. Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014;37(9):2522-2532.
13. van Walraven C, Davis D, Forster AJ, et al. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol. 2004;57(7): 672-682.
14. Beyersmann J, Gastmeier P, Wolkewitz M, et al. An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol. 2008; 61(12):1216-1221.
15. Ioannou GN, Boyko EJ. Metformin and colorectal cancer risk in diabetic patients. Diabetes Care. 2011;34(10):2336-2337.
16. Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(8): 707-710.